Comments
Drugmaker Cipla has granted Salix Pharmaceuticals exclusive rights under certain patent applications in the ‘Rifaximin complexes’ family, used as antibiotics. The grant is on a worldwide basis, excluding the countries of Asia (other than Japan) and Africa, a Cipla note said. Salix will make an upfront payment and milestone payments to Cipla, under the new licence agreement regarding ‘Rifaximin Complexes’ patent rights. Salix also will pay a royalty on net sales of products covered by the licensed patents.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.